Radiotherapy combined with third-generation EGFR tyrosine kinase inhibitor in first-line treatment of advanced oligometastatic non-small cell lung cancer: a single-center, retrospective study | Synapse
March 3, 2026Open Access
Radiotherapy combined with third-generation EGFR tyrosine kinase inhibitor in first-line treatment of advanced oligometastatic non-small cell lung cancer: a single-center, retrospective study
Key Points
Improved progression-free survival was observed with combined treatment for EGFR-mutant advanced NSCLC.
The analysis indicates that radiotherapy plus EGFR tyrosine kinase inhibitors enhances treatment outcomes.
Retrospective study provided insights into the safety profile and effectiveness of this combined approach.
The findings suggest further investigation could validate the benefits in broader patient populations.
Abstract
RT (BED10 ≥50 Gy) combined with third-generation EGFR-TKI therapy improved PFS with favorable safety in EGFR-mutant advanced oligometastatic NSCLC.